Sartorius has revealed its sales figures for the first quarter of the year, demonstrating growth in its group sales revenue and earnings of 12.2% and 17%, respectively.
Growth
“Both divisions successfully started off the current year,” said Dr Joachim Kreuzburg, CEO and executive board chairman of Sartorius. “Lab Products & Services achieved considerable organic growth, and with the acquisition of Essen BioScience, it added another innovative product family to its bioanalytics portfolio and further growth potential.”
The company reported that there was a return to normal rates in the Bioprocess Solutions growth, which had been above average over the last two years. “In particular, business development in the Americas region was somewhat more moderate in the first quarter; however, we expect demand to pick up over the year,” explained Kreuzburg.
During the first quarter, the company’s sales revenue increased from €301.9 million to €343.1 million. Strongest growth was seen in the Asia Pacific region, where sales were up 33.3%. The EMEA region sales were up 8.9% and the Americas region sales saw an increase of 4.9%.
Guidance for the year has been confirmed by Sartorius and raised as a result of consolidation of acquisitions. It is projected that sales will grow by about 12–16% for the full year and the earnings will increase slightly more, by a half a percentage, over last year’s figure.